What the FDA labels say about taking them together
Digoxin and lasmiditan
Lasmiditan's FDA label of January 8, 2026 names digoxin in its drug interactions section; the digoxin labels PlainMeds reads (3) do not name lasmiditan. The lasmiditan label: “P-glycoprotein (P-gp) Transporter Substrates Coadministration of REYVOW with P-gp substrates where a small change in substrate plasma concentration may lead to serious toxicities (e.g., digoxin) is not recommended.”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the lasmiditan FDA label on DailyMed (effective January 8, 2026, Eli Lilly and Company).
What does the digoxin label say about lasmiditan?
Digoxin's label (effective December 5, 2024) and its 2 other brand-application labels do not name lasmiditan in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the lasmiditan label say about digoxin?
Lasmiditan label, drug interactionsP-glycoprotein (P-gp) Transporter Substrates Coadministration of REYVOW with P-gp substrates where a small change in substrate plasma concentration may lead to serious toxicities (e.g., digoxin) is not recommended [see Clinical Pharmacology ( 12.3 )].
Source: FDA drug label (Reyvow), Eli Lilly and Company, effective January 8, 2026 (SPL set aea3358c-ff41-4490-9e6d-c7bf7b3de13f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Lasmiditan | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | Migraine |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | $88.77 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once